Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
June 03 2025 - 6:30AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of May 2025
Commission
File Number: 001-42527
Basel
Medical Group Ltd
6
Napier Road,
Unit
#02-10/11 Gleneagles Medical Centre
Singapore
258499
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Basel
Medical Group Ltd |
|
|
|
|
By: |
/s/
Darren Yen Feng Chhoa |
|
Name: |
Dr.
Darren Yen Feng Chhoa |
|
Title: |
Chief
Executive Officer |
|
|
|
|
Date: |
June
3, 2025 |
|
Exhibit
99.1

Basel
Medical Group Ltd Reaffirms Strong Financial Position Amid Market Volatility
Singapore,
May 29, 2025 (GLOBE NEWSWIRE) — Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today reaffirmed the strength
of its underlying financial performance and strategic outlook, despite recent volatility in its share price.
Speaking
on behalf of the Board and management team, BMGL’s Chief Executive Officer, Dr Darren Chhoa stated, “While recent movements
in our share price may raise questions, I want to assure our shareholders and stakeholders that the fundamentals of BMGL remain strong
and resilient. Our financial performance continues to be robust, with our subsidiaries winning new sizable contracts particularly in
the supply chain, and we remain on track with our acquisition growth strategy.”
“We
believe that the recent share price decline does not reflect the intrinsic value of our business nor the solid progress we’ve made.
BMGL has consistently demonstrated strong operational execution, disciplined capital management, and a commitment to delivering sustainable
value for shareholders.”
About
Basel Medical Group Ltd
Basel
Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well
as neurosurgical treatments. Our operations are based in Singapore, with our clinics being at 6 Napier Road, Unit #02-10/11 and Unit
#03-07, Gleneagles Medical Centre. Over the last 20 years, our group has forged strong and lasting relationships with a large base of
corporations, in particular those in the construction, marine and oil & gas industries, which underpin our robust business model.
As an orthopedic service provider in Singapore with a track record of over 20 years, we are well-positioned to ride the wave of growth
opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations, rising income levels,
increasing private insurance coverage, government effort and expenditure on healthcare, growing sports participation rate and Singapore’s
position as a premium destination for healthcare services in Asia. Our management and medical practitioner team comprises a roster of
orthopedic and neurosurgery specialists, corporate finance and healthcare partnership specialists. Basel Medical Group Ltd serves as
the holding company of our group and we conduct our operations through our operating subsidiaries based in Singapore. For more information,
please visit the Company’s website: www.baselmedical.com.
Forward-Looking
Statements
Certain
statements in this announcement are forward-looking statements, which involve known and unknown risks and uncertainties and are based
on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations,
business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”,
“anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”,
“may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”,
“will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update
or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations,
except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results
may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results
in the Company’s filings with the SEC.
Media
Contact:
Basel
Medical Group Ltd
+65
6291 9188
contact@baselmedical.com
www.baselmedical.com
Basel Medical (NASDAQ:BMGL)
Historical Stock Chart
From Jun 2025 to Jul 2025
Basel Medical (NASDAQ:BMGL)
Historical Stock Chart
From Jul 2024 to Jul 2025